Alto Neuroscience faces securities fraud lawsuit
Analysis based on 6 articles · First reported Aug 25, 2025 · Last updated Sep 19, 2025
The market is impacted by the potential financial liabilities and reputational damage to Alto Neuroscience due to the class action lawsuit. Investors who purchased Alto Neuroscience stock during the specified period may recover losses, while the stock price of Alto Neuroscience could face downward pressure.
Levi & Korsinsky has initiated a class action securities lawsuit against Alto Neuroscience, Inc. The lawsuit alleges that Alto Neuroscience made false and misleading statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, and consequently overstated its clinical, regulatory, commercial, business, and financial prospects. Investors who acquired Alto Neuroscience common stock during its initial public offering on or about February 2, 2024, and/or Alto Neuroscience securities between February 2, 2024, and October 22, 2024, are urged to join the lawsuit. Joseph E. Levi and Levi & Korsinsky are listed as contacts for the firm.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard